Journal ArticleOPEN ACCESS

APE1 shRNA‐loaded cancer stem cell‐derived extracellular vesicles reverse Erlotinib resistance in non‐small cell lung cancer via the IL‐6/STAT3 signalling

  • Tang C
  • Qin L
  • Gao Y
  • et al.
Clinical and Translational Medicine (2022) 12(5)
DOI: 10.1002/ctm2.876
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Graphical Abstract Collectively, these data indicate that APE1 confers Erlotinib resistance by activating the IL-6/STAT3 signaling, suggesting targeting APE1 as a possible therapeutic target in Erlotinib-resistant NSCLC. Clin. Transl. Med. 2022;12:e876. wileyonlinelibrary.com/journal/ctm2 https://doi.

Cite

CITATION STYLE

APA

Tang, C., Qin, L., Gao, Y., Chen, T., Xu, K., Liu, T., & Ren, T. (2022). APE1 shRNA‐loaded cancer stem cell‐derived extracellular vesicles reverse Erlotinib resistance in non‐small cell lung cancer via the IL‐6/STAT3 signalling. Clinical and Translational Medicine, 12(5). https://doi.org/10.1002/ctm2.876

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free